AbCellera Biologics Inc. Annual Income Tax Expense (Benefit) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
AbCellera Biologics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2020 to 2023.
  • AbCellera Biologics Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$11.5M, a 8.05% decline year-over-year.
  • AbCellera Biologics Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$26.4M, a 4.8% increase year-over-year.
  • AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2023 was -$27.6M, a 134% decline from 2022.
  • AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2022 was $80.6M, a 22.7% increase from 2021.
  • AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2021 was $65.7M, a 68.8% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$27.6M -$108M -134% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 $80.6M +$14.9M +22.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 $65.7M +$26.8M +68.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-20
2020 $38.9M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.